cytologic screening

cy·to·log·ic screen·ing

a screening for the detection of early disease, usually cancer, through microscopic examination of a cellular specimen by inspecting each cell and structure present, usually at ×100 magnification with a mechanical stage, so that all areas are screened; the findings are evaluated and significant abnormalities are flagged (for example, by dotting the cover slip) for further evaluation by a cytopathologist. This screening is usually performed by a cytotechnologist, but at times is done by automated machine prescreening.
References in periodicals archive ?
Some experts recommend anal cytologic screening or high-resolution anoscopy for HIV-positive men and women, but it's worth noting that strategy hasn't been incorporated into any national practice guidelines.
Whether cytologic screening is efficacious in preventing anal cancer remains unproven (though probable), while cytology screening has proved valuable in preventing cervical cancer (though not in a randomized trial).
Digital anal-rectal examination and anal cytologic screening followed by annual screening is recommended in the following women:
cohort of 19,512 women who underwent routine cytologic screening when they were aged 16-94 years at baseline in 1989-1990.
Automated screening instruments have improved the sensitivity of cytologic screening.
These data support the need for studies of anal cytologic screening of HIV-positive women.
For HPV or cytologic screening, the nurse-midwives collected cervical cells for testing; women received results within two weeks, and those who tested positive were given appointments for colposcopy, biopsy and treatment.
The availability of a non cytologic screening method not requiring a vaginal speculum examination may reduce underscreening in women who have access to health care.
Liquid-based Pap tests have been shown to increase the sensitivity of cytologic screening in most, although not all studies.
A computer-based model of the natural history of HPV and cervical cancer developed by the Harvard School of Public Health considered different cancer prevention policies, including vaccination against HPV types 16 and 18 (initiated at the age of 12 years), cytologic screening (initiated at 18, 21, 25, 30, or 35 years,) and combined vaccination and screening strategies.